Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferons and bladder cancer.

D H Brown1, T T Wagner, R R Bahnson

  • 1Division of Urology, Ohio State University, Columbus, USA.

The Urologic Clinics of North America
|March 4, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

FACTORS AFFECTING THE KINETICS OF INTRA-AND EXTRACELLULAR CADMIUM UPTAKE BY THE MOSS RHYTIDIADELPHUS SQUARROSUS.

The New phytologist·2021
Same author

Ionic control of intracellular and extracellular Cd uptake by the moss Rhytidiadelphus squarrosus (Hedw.) Warnst.

The New phytologist·2021
Same author

The effect of seawater on the metabolism of some seashore and inland mosses.

Oecologia·2017
Same author

Correlation between clinical and MRI assessment of depth of invasion in oral tongue squamous cell carcinoma.

Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale·2016
Same author

The changes in glutamic dehydrogenase activity following illumination of etiolated barley seedlings.

Planta·2014
Same author

The influence of inorganic nitrogen supply on carbohydrate and related metabolism in the blue-green alga, Anabaena cylindrica Lemm.

Planta·2014
Same journal

An Unprecedented Era of Innovation in Non-Muscle-Invasive Bladder Cancer.

The Urologic clinics of North America·2026
Same journal

Hubert Humphrey's Bladder Cancer: If He Could Have Time Traveled, Would that Have Changed the Outcome?

The Urologic clinics of North America·2026
Same journal

Key Clinical Trials Shaping the Future of Superficial High-Risk Bladder Cancer Management.

The Urologic clinics of North America·2026
Same journal

Future Directions: Artificial Intelligence and Digital Tools in Bladder Cancer Care.

The Urologic clinics of North America·2026
Same journal

Economic Considerations in the Management of Superficial Bladder Cancer.

The Urologic clinics of North America·2026
Same journal

Patient-Centered Approaches to Non-Muscle-Invasive Bladder Cancer Care.

The Urologic clinics of North America·2026
See all related articles

Intravesical interferon offers a promising, low-side-effect treatment for superficial bladder cancer, potentially reducing recurrence and progression. Research is exploring its combination with other therapies for enhanced efficacy.

Area of Science:

  • Oncology
  • Immunology
  • Urology

Background:

  • Intravesical immunotherapy, including Bacillus Calmette-Guérin (BCG), is a standard treatment for superficial bladder cancer.
  • Interferon demonstrates potential in modulating immune responses against tumor cells.

Purpose of the Study:

  • To evaluate the efficacy of intravesical interferon in managing superficial bladder cancer.
  • To compare the side effect profile and dropout rates of interferon versus BCG therapy.
  • To explore the potential of interferon in combination therapies.

Main Methods:

  • Intravesical instillation of interferon as an immunotherapeutic agent.
  • Monitoring of tumor recurrence and progression rates.
  • Assessment of patient-reported side effects and treatment adherence.

Related Experiment Videos

Main Results:

  • Interferon shows promise in reducing superficial bladder cancer recurrence and progression.
  • Intravesical interferon is associated with minimal side effects and a low dropout rate compared to BCG.
  • Current research investigates combination therapies involving interferon.

Conclusions:

  • Intravesical interferon represents a viable and well-tolerated treatment option for superficial bladder cancer.
  • Its favorable side effect profile makes it an attractive alternative or adjunct to existing therapies.
  • Further research into combination strategies may enhance its therapeutic impact.